Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 3, 1996, Pages 296-300

  Bafaloukos, D ^a,e,f   Pavlidis, N ^b,f   Fountzilas, G ^c,f   Skarlos, D ^d,f   Klouvas, G ^b,f   Makrantonakis, P ^c,f   Giannakakis, T ^d,f   Tsavaris, N ^a,f   Kosmidis, P ^a,f  

^a METAXA CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

^d AGII ANARGIRI CANCER HOSPITAL   (Greece)

^e Metaxa's Cancer Institute of Piraeus   (Greece)

^f Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Chemotherapy; Interferon; Maintenance therapy; Malignant melanoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; RECOMBINANT ALPHA2A INTERFERON; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MELANOMA; MORTALITY; NEUTROPENIA; PNEUMONIA; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; FEMALE; HUMANS; INTERFERON ALFA-2A; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; VINBLASTINE;

EID: 0029895155     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199606000-00018     Document Type: Article

References (34)

1. McClay EF, Mastrangelo MJ. Systemic chemotherapy for metastatic melanoma. Semin Oncol 1988;15:569-77.
2. Retsas S, Bayliss M, Sheikh N, et al. Chemotherapy of malignant melanoma: the European experience. Rev Med Interne 1990;11: 51-8.
3. Feun LG. The natural history of resectable metastatic melanoma. Cancer 1982;50:1656-63.
4. Nathanson L, Kaufman SD, Carey RW. Vinblastine, infusion bleomycin, and cis-dischlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer 1981;48:1290-4.
5. Evans LM, Casper ES, Rosembluth R, et al. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treal Rep 1987;71:171-2.
6. Mastrangelo MJ, Schultz S, Kane M, et al. Newer immunologic approaches to the treatment of patients with melanoma. Semin Oncol 1988;15:589-94.
7. Retsas S, Priestman TJ, Newton KA, et al. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 1983;51:273-6.
8. Balkwill FR. Antitumor effects of interferons in animals. In: Finter ND, Oldham RK, eds. Interferon, volume 4: in vivo and clinical studies. Amsterdam: Elsevier Science, 1985:23-45.
9. Namba M, Yamamoto S, Tanaka H, et al. In vitro and vivo studies in potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. Cancer 1984;54:2262-7.
10. Welander CE, et al. In: Kisner D, Smith J, eds. Interferon alfa-2: pre-clinical and clinical evaluation. Boston: Martinus Nijhoff, 1985:29-40.
11. Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 1988;48:4868-73.
12. Von Hoff DD, Satosy G, Brown TD, et al. Rationale for and conduct of phase I clinical trial with interferon alpha-2b plus doxorubicin. Semin Oncol 1986;13:72-7.
13. Welander CE, Morgan TM, Homesley HD, et al. Combined recombinant human interferon alpha and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985;35:721-9.
14. Aapro M, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other therapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983;10:161-6.
15. Hayward JL, Rubens RD, Carbone PP, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35: 292-8.
16. WHO. WHO handbook for reporting results of cancer treatment. Offset publication no. 48. Geneva; WHO, 1979.
17. Armitage P, Berry G. Statistical methods in clinical research. 2nd ed. Oxford: Blackwell Scientific, 1987.
18. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
19. Kaplan EI, Meier P. Nonparametric estimation from imcomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Analysis and examples. Br J Cancer 1977;35:1-39.
21. Retsas S, Quigley M, Pectasides D, et al. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Cancer 1994;73:2119-30.
22. Green MD, Speyer J, Wernz J, et al. Doxorubicin and interferon: rationale and clinical experience. Cancer Treat Rev 1985;12:61-7.
23. Durie BG, Clouse L, Braich T, et al. Interferon alpha-2b-cyclo-phosphamide combination studies: in vitro and phase I-II clinical results. Semin Oncol 1986;13:84-8.
24. Berens ME, Saito T, Welander CE, et al. Antitumor activity of new antracycline analogues in combination with interferon alpha. Cancer Chemother Pharmacol 1987;19:301-6.
25. Carmicael J, Fergusson RJ, Wolf CR, et al. Augmentation of cytotoxicity of chemotherapy by human α-interferons in human non small cell lung cancer xenografts. Cancer Res 1986;46:4916-20.
26. Von Hoff DD, Sarosy GA, Brown TD, et al. Rationale for and conduct of a phase I clinical trial with interferon alpha-2b plus doxorubicin. Semin Oncol 1986;13:72-7.
27. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991;9:1403-8.
28. Gundersen S, Flokkmann A. Interferon in combination with vinblastine in advanced malignant melanoma. Cancer 1989;64: 1617-9.
29. Hersey P, Mcleod GR, Thomson DB. Treatment of advanced malignant melanoma with recombinant interferon alpha-2a in combination with DTIC: long-term follow-up of two phase II studies. Br. J Heamalology 1991;79:60-6.
30. Creagan ET, Ahmann DL, Schutt AJ, Green SJ. Phase II study of the combination of vinblastine, bleomycin and cisplatin in advanced malignant melanoma. Cancer Treat Rep 1981;66:567.
31. Canadian Melanoma Group. Vinblastine, bleomycin and cis-platinum for the treatment of metastatic malignant melanoma. J Clin Oncol 1984;2:131.
32. Balch C, Houghton A, Peters L. Cutaneous melanoma; In: De Vita VT, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology. Philadelpia: Lippincott, 1989:1509-33.
33. Nordlund JJ, Kirkwookd JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1984;9:689-96.
34. Richards JM, Mehtu N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1138-43.